Stoke Therapeutics (NASDAQ:STOK) Shares Up 4.5%

Stoke Therapeutics, Inc. (NASDAQ:STOK) rose 4.5% on Thursday . The stock traded as high as $12.26 and last traded at $12.25. Approximately 228,273 shares changed hands during mid-day trading, a decline of 76% from the average daily volume of 960,156 shares. The stock had previously closed at $11.72.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on STOK shares. Cantor Fitzgerald restated an “overweight” rating on shares of Stoke Therapeutics in a research note on Thursday, April 4th. TD Cowen upgraded Stoke Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 26th. HC Wainwright restated a “buy” rating and issued a $35.00 target price on shares of Stoke Therapeutics in a research note on Tuesday, March 26th. Needham & Company LLC restated a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a research note on Thursday, April 11th. Finally, Canaccord Genuity Group lifted their price objective on Stoke Therapeutics from $18.00 to $21.00 and gave the company a “buy” rating in a research note on Tuesday, March 26th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $19.63.

Stoke Therapeutics Price Performance

The company has a 50 day moving average price of $8.76 and a two-hundred day moving average price of $5.99. The stock has a market cap of $557.92 million, a PE ratio of -5.08 and a beta of 0.77.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings data on Monday, March 25th. The company reported ($0.60) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.02. The firm had revenue of $2.80 million during the quarter, compared to the consensus estimate of $3.70 million. As a group, equities analysts predict that Stoke Therapeutics, Inc. will post -2.28 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Stephen J. Tulipano sold 4,116 shares of Stoke Therapeutics stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total value of $25,107.60. Following the completion of the sale, the chief financial officer now owns 20,746 shares of the company’s stock, valued at $126,550.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Stoke Therapeutics news, insider Barry Ticho sold 10,000 shares of the business’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $4.80, for a total transaction of $48,000.00. Following the completion of the sale, the insider now owns 6,981 shares of the company’s stock, valued at $33,508.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Stephen J. Tulipano sold 4,116 shares of the business’s stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total value of $25,107.60. Following the sale, the chief financial officer now directly owns 20,746 shares of the company’s stock, valued at approximately $126,550.60. The disclosure for this sale can be found here. Insiders sold 3,632,741 shares of company stock valued at $41,983,115 over the last 90 days. Company insiders own 12.30% of the company’s stock.

Institutional Trading of Stoke Therapeutics

Several hedge funds have recently bought and sold shares of STOK. Lynx1 Capital Management LP bought a new stake in Stoke Therapeutics during the third quarter valued at about $6,738,000. Goldman Sachs Group Inc. boosted its stake in shares of Stoke Therapeutics by 976.1% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,391,431 shares of the company’s stock worth $7,319,000 after acquiring an additional 1,262,126 shares during the period. Wellington Management Group LLP bought a new position in shares of Stoke Therapeutics in the first quarter worth about $25,011,000. Millennium Management LLC boosted its stake in shares of Stoke Therapeutics by 121.9% in the second quarter. Millennium Management LLC now owns 949,658 shares of the company’s stock worth $12,545,000 after acquiring an additional 521,661 shares during the period. Finally, BlackRock Inc. boosted its stake in shares of Stoke Therapeutics by 24.3% in the second quarter. BlackRock Inc. now owns 2,293,670 shares of the company’s stock worth $24,382,000 after acquiring an additional 448,175 shares during the period.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.